PSTV (Plus Therapeutics) Long-Term Debt: $0.00 Mil (As of Mar. 2026)


PSTV Plus Therapeutics Inc PSTV
26 GF Score
Price $3.98
! 2 Warning Signs
View Full Analysis

What is Plus Therapeutics Long-Term Debt?

Plus Therapeutics PSTV -4.33% 26 Long-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus rates PSTV with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

Plus Therapeutics's Long-Term Debt for the quarter that ended in Mar. 2026 was $0.00 Mil.

Plus Therapeutics  (NAS:PSTV) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Plus Therapeutics Long-Term Debt Related Terms

Plus Therapeutics Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Plus Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Plus Therapeutics Long-Term Debt Chart

Plus Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.01 3.79 0.00 0.00 0.00

Plus Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
PSTV
26GF Score
Plus Therapeutics Inc PSTV
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.00 Mil mean?
Plus Therapeutics (PSTV) has a Long-Term Debt of $0.00 Mil as of Mar. 2026.
Is Plus Therapeutics' Long-Term Debt too high?
Plus Therapeutics' current Long-Term Debt is $0.00 Mil. Overall, Plus Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Plus Therapeutics' Long-Term Debt compare to KYNB and VTGN?
Plus Therapeutics' Long-Term Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Plus Therapeutics's current Long-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Plus Therapeutics stock overvalued right now?
Plus Therapeutics (PSTV) has a current Long-Term Debt of $0.00 Mil. The current Long-Term Debt is $0.00 Mil. Plus Therapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Plus Therapeutics (PSTV), the current Long-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Plus Therapeutics Business Description

Other Exchanges XMP1:Germany
Address 6420 Levit Green Boulevard, Suite 210, Houston, TX, USA, 77021
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
26GF Score

Get the complete analysis for PSTV

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.98
Price